Avanafil
113 interactions 1 explained in plain English 299 cited references
Also sold as:
Stendra
Stendra®
About Avanafil
Avanafil is used to treat erectile dysfunction (ED: impotence; inability to get or keep an erection in men). Avanafil is in a class of medications called phosphodiesterase (PDE) inhibitors. It works by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Avanafi… Read the full Avanafil drug information page →
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Aug 9, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Most serious with:
Nitroglycerin Transdermal Patch
Isosorbide Mononitrate
Amyl Nitrite
Isosorbide Dinitrate
Isosorbide
Erythrityl Tetranitrate
Major
Avanafil Ivosidenib Tibsovo Reduced exposure of sensitive CYP3A4 substrates and risk of loss of efficacy Details Avanafil Ketoconazole Extina Reduced avanafil clearance and increased avanafil exposure Details Avanafil Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Avanafil Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Avanafil Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure Details Avanafil Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avanafil Lopinavir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Mifepristone Korlym Increased CYP3A4 substrate exposure Details Avanafil Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Avanafil Nefazodone Decreased avanafil clearance and increased avanafil plasma concentrations Details Avanafil Nelfinavir Viracept Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Netupitant Increased exposure of CYP3A4 substrate Details Avanafil Nevirapine Viramune Decreased avanafil plasma concentrations Details Avanafil Nirmatrelvir Increased avanafil exposure Details Avanafil Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Avanafil Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Avanafil Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avanafil Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Avanafil Posaconazole Noxafil Increased avanafil exposure Details Avanafil Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avanafil Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Avanafil Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Avanafil Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Avanafil Ritonavir Norvir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Saquinavir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Sepiapterin An increased risk of hypotension Details Avanafil Sildenafil Liqrev Potentiation of hypotensive effects Details Avanafil Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Avanafil Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Avanafil Telaprevir Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Telithromycin Decreased avanafil clearance and increased avanafil plasma concentration Details Avanafil Terazosin Hytrin® Increased risk of hypotension Details Avanafil Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Avanafil Voriconazole Vfend Increased avanafil exposure and an increased efficacy of avanafil-related adverse effects Details Avanafil Ketoconazole Topical Extina® Foam Reduced avanafil clearance and increased avanafil exposure Details Avanafil Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure Details Avanafil Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure DetailsModerate
Avanafil Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Avanafil Alfuzosin UroXatral Increased risk of hypotension Details Avanafil Amprenavir Decreased avanafil clearance and increased avanafil plasma concentrations DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.